Warburg revisited: imaging tumour blood flow and metabolism

被引:105
作者
Miles, K. A. [1 ]
Williams, R. E. [1 ]
机构
[1] Brighton & Sussex Med Sch, Brighton BN1 9PX, E Sussex, England
来源
CANCER IMAGING | 2008年 / 8卷 / 01期
关键词
Angiogenesis; Response evaluation; Tumour characterisation; Tumour metabolism; Tumour perfusion;
D O I
10.1102/1470-7330.2008.0011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the 1930s, Otto Warburg reported that anaerobic metabolism of glucose is a fundamental property of all tumours, even in the presence of an adequate oxygen supply. He also demonstrated a relationship between the degree of anaerobic metabolism and tumour growth rate. Today, this phenomenon forms the basis of tumour imaging with fluorodeoxyglucose positron emission tomography (FDG-PET). More recently, Folkman has demonstrated that malignant growth and survival are also dependent on tumour vascularity which is increasingly evaluated in vivo using techniques such as contrast enhanced computed tomography or magnetic resonance imaging (MRI). Although it is reasonable to hypothesise that the metabolic requirements of tumours are mirrored by alterations in tumour haemodynamics, the relationship between tumour blood flow and metabolism is in fact complex. A well-developed tumour vascular supply is required to ensure a sufficient delivery of glucose and oxygen to support the metabolism essential for tumour growth. However, an inadequate vascularisation of tumour will result in hypoxia, a factor that is known to stimulate anaerobic metabolism of glucose. Thus, the balance between tumour blood flow and metabolism will be an important indicator of the biological status of a tumour and hence the tumour's likely progression and response to treatment. This article reviews the molecular biology of tumour vascularisation and metabolism, relating these processes to currently available imaging techniques while summarising the imaging studies that have compared tumour blood flow and metabolism. The potential for vascular metabolic imaging to assess tumour aggression and sub-classify treatment response is highlighted. © 2008 International Cancer Imaging Society.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 34 条
[31]  
Mankoff D.A., Dunnwald L.K., Gralow J.R., Et al., Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy, J Nucl Med, 44, pp. 1806-1814, (2003)
[32]  
Kurdziel K.A., Figg W.D., Carrasquillo J.A., Et al., Using positron emission tomography 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose, <sup>11</sup>CO, and <sup>15</sup>O-water for monitoring androgen independent prostate cancer, Mol Imaging Biol, 5, pp. 86-93, (2003)
[33]  
Herbst R.S., Mullani N.A., Davis D.W., Et al., Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin, J Clin Oncol, 20, pp. 3804-3814, (2002)
[34]  
Miles K.A., Perfusion CT-PET: Opportunities for combined assessment of tumor vascularity and metabolism, pp. 215-229, (2007)